Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 60.66M | 59.42M | 57.94M | 58.42M | 56.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.66M | 59.42M | 57.94M | 58.42M | 56.88M |
| Cost of Revenue | 30.44M | 30.90M | 31.36M | 29.15M | 29.31M |
| Gross Profit | 30.22M | 28.52M | 26.58M | 29.28M | 27.57M |
| SG&A Expenses | 21.81M | 20.47M | 19.87M | 18.44M | 17.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.59M | 60.45M | 60.17M | 55.96M | 53.87M |
| Operating Income | -932.00K | -1.03M | -2.22M | 2.46M | 3.01M |
| Income Before Tax | -892.00K | -929.00K | -2.40M | 2.36M | 2.84M |
| Income Tax Expenses | 243.00K | 246.00K | -55.00K | -74.00K | -81.00K |
| Earnings from Continuing Operations | -1.14 | -1.18 | -2.34 | 2.43 | 2.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 31.00K | 31.00K | 31.00K | 31.00K | -- |
| Net Income | -1.10M | -1.14M | -2.31M | 2.46M | 2.92M |
| EBIT | -932.00K | -1.03M | -2.22M | 2.46M | 3.01M |
| EBITDA | 401.00K | 347.00K | -773.00K | 3.97M | 4.56M |
| EPS Basic | -0.08 | -0.08 | -0.17 | 0.18 | 0.21 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.09 | 0.12 | 0.14 |
| EPS Diluted | -0.08 | -0.08 | -0.17 | 0.16 | 0.19 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.09 | 0.11 | 0.13 |
| Average Basic Shares Outstanding | 55.49M | 55.38M | 55.22M | 55.03M | 54.84M |
| Average Diluted Shares Outstanding | 56.15M | 56.05M | 55.89M | 56.36M | 55.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |